Nimbus Therapeutics
PrivateLast Round
VC Round
Sep 6, 2023
Total Funding Raised
$68.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nimbus Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a VC Round in September 2023.
Nimbus Therapeutics is a biotechnology company that develops small molecule compounds aimed at discovering innovative medicines and enhancing drug development for metabolic diseases, cancer, and immune-inflammatory disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nimbus Therapeutics Comparables
Compare Nimbus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Antares Therapeutics | 85% | |
| Insitro | 83% | |
| HotSpot Therapeutics | 83% |
For institutional investors. Book with your work email.
Nimbus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 6, 2023 | ||||
| VC Round | Sep 12, 2022 | ||||
| VC Round | Jul 13, 2021 | ||||
| VC Round | Oct 14, 2020 | ||||
| VC Round | Jun 5, 2018 | ||||
Series B | Mar 18, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nimbus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | VC Round |
| Access Industries | VC Round |
| Bain Capital Life Sciences | VC Round |
| RA Capital Advisors | VC Round |
| RA Capital Management | VC Round |
| SV Health Investors | VC Round |
| GV | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 58% MoM, reaching 12.1K.
- Apr 15, 2026
Presenting new data on SIK2 inhibitor program at IMMUNOLOGY2026.
For institutional investors. Book with your work email.
Nimbus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nimbus Therapeutics's valuation, stock price, and market status.
Is Nimbus Therapeutics a public or private company?
Nimbus Therapeutics is a private company.
What is the current stock price of Nimbus Therapeutics?
Nimbus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nimbus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nimbus Therapeutics worth (valuation)?
Valuation information for Nimbus Therapeutics is not publicly available.
Can I buy Nimbus Therapeutics stock?
Nimbus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nimbus Therapeutics's last funding round?
Nimbus Therapeutics's most recent funding round was VC Round on September 6, 2023.
Who are the main investors in Nimbus Therapeutics?
Key investors in Nimbus Therapeutics include Bain Capital Life Sciences, RA Capital Management, SV Health Investors, GV, Lilly Ventures.
Will Nimbus Therapeutics IPO soon?
No public IPO plans have been announced for Nimbus Therapeutics.
How can I track Nimbus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nimbus Therapeutics's shares on secondary markets.